Despite improvements in perioperative management, radical cystectomy (RC) remains still associated with mortality rates of up to 9% within 90 days after surgery across all age groups ([@r1]). With this in mind, attempts to minimize postoperative complications are essential.

Compared to other disciplines such as gastrointestinal surgery ([@r2]), the influence of the patient's nutritional status on the outcome of RC has not been extensively studied. However, since nutritional status is assumed to influence postoperative morbidity, the authors of the randomized controlled clinical trial published in this issue are to be commended for their pioneering work ([@r3]). Hamilton-Reeves *et al.* comparatively analyzed a total of 29 men that were randomly assigned to receive either a Specialized IMmunonutrition (SIM; L-arginine, omega-3 fatty acids, dietary nucleotides; n=14) or a standard oral nutrition supplement without immunomodulators (ONS; n=15) for five days pre- and postoperatively, respectively, in order to evaluate the impact on acute inflammatory response (IR) and arginine status after RC. Using T-helper (Th)1-Th2 balance as a surrogate for the IR, the authors found that the intake of this SIM had a significant impact on the Th1-Th2 balance which was shifted towards a Th1 response with the SIM compared to ONS. Thus, with immunonutrition patients may benefit since a shift toward a predominant Th1 response is perhaps more likely to be associated with less postoperative complications ([@r4]). The findings of the current SIM study on RC are in line with findings from large randomized control trials in gastrointestinal surgery ([@r5]-[@r7]) that the intake of SIM counteracts Th1-Th2 imbalance after major surgery.

Also, IL-6 levels were lower in the SIM group compared to ONS showing a reduced IR on the second postoperative day. Other data from studies on hepatobiliary surgery also support this finding of a reduced IL-6 level with immunonutrition, which might be protective against increased muscle catabolism and complications ([@r8],[@r9]). The intake of SIM was also associated with higher serum ornithine levels 30 days after surgery compared to ONS. Ornithine potentially has a beneficial effect on would healing with increased collagen formation due higher proline and polyamine availability ([@r10]). SIM also seemed to lead to less pronounced muscle loss two weeks after RC. Interestingly, the serum level of C-reactive protein was not significantly different between SIM and ONS.

Half of the patients in the SIM group received neoadjuvant chemotherapy which in itself may lead to an impaired nutritional status. Immunonutrition might be a beneficial early intervention to avoid malnutrition and consecutive muscle loss with added chemotherapy ([@r11]).

Enhanced Recovery After Surgery (ERAS) protocols are currently widely used in RC patients, with a better and more standardized perioperative care, earlier recovery and less complications ([@r12]). ERAS was not included in the current study nor was a standardized assessment of complication. Thus, comparing the findings of this study to current practice patterns is not possible.

Overall, although the findings are of high interest, the small sample size, the short follow-up and the non-standardized design in some respects make this study, although an RCT, a pilot study. Further larger and more elaborate studies are needed as many of the findings in this small trial may be incidental and the interpretations are still largely hypothetical. The underlying hypothesis, that immunonutrition may well improve results of RC is extremely interesting.
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